Results 101 to 110 of about 3,500 (175)

Reimagining Pt(II) Anticancer Agents: The Role of Ferrocene in Monofunctional Chemotherapeutic Compounds. [PDF]

Inorg Chem
Miguel S, Ortín-Fernández J, Gómez-Pastor S, Moliné MÁ, Sánchez-Murcia PA, Corral I, Sanz-Rodríguez F, González-Vadillo AM.   +7 more
europepmc   +1 more source

A pragmatic, single-arm clinical trial of a dose modification algorithm for preventing cytopenia-related delays during FOLFOX chemotherapy. [PDF]

Support Care Cancer
Wright HN, Tosteson TD, Hourdequin KC, Ripple GH, Fuld AD, Dragnev KH, Amin M, Muralikrishnan S, McGrath EB, Stannard MG, Schofield LL, Lord-Halvorson S, Tosteson ANA, Brooks GA.   +13 more
europepmc   +1 more source

Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer. [PDF]

Sci Rep
Song R, Chen Z, Zheng T, Huang J, Cheng Y.   +4 more
europepmc   +1 more source

Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review. [PDF]

Oncol Res
Alemzadeh E, Allahqoli L, Mazidimoradi A, Alemzadeh E, Ghasemi F, Salehiniya H, Alkatout I.   +6 more
europepmc   +1 more source

Computational Analysis of a Next-Generation Platinum-Based Chemotherapies that Induce DNA Double-Strand Breaks. [PDF]

J Chem Inf Model
Guimarães AR, Ballesteros ÓR, Rivilla I, Olaizola I, Odriozola-Gimeno M, de Cózar A, de Sancho D, Lopez X, Banales JM, Cossío FP.   +9 more
europepmc   +1 more source

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis. [PDF]

ESMO Open
Trovato G, Rossini D, Guidolin A, Su YY, Shan YS, Chiang NJ, Chou WC, Bai LY, Bagalà C, Bensi M, Niger M, Marchesi S, Garattini SK, Michelotti A, Pretta A, Scartozzi M, Vivaldi C, Bartalini L, Procaccio L, Bergamo F, Antonuzzo L, Chen LT, Salvatore L, Tortora G.   +23 more
europepmc   +1 more source

Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment. [PDF]

ESMO Open
Ambrosini M, Blons H, Garinet S, Mulot C, Le Corre D, Mouillet-Richard S, Pietrantonio F, Sroussi M, Lepage C, Laurent-Puig P, Taieb J.   +10 more
europepmc   +1 more source

Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study. [PDF]

Cancer Immunol Immunother
Lai M, Li S, Jin Z, Chang M, Li F, Yang P, He Y, Zhang Q.   +7 more
europepmc   +1 more source

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma. [PDF]

Oncologist
Lee MS, Chao J, Mulcahy MF, Kasi PM, Alistar AT, Mukherjee S, Akce M, Moore DT, McRee AJ, Somasundaram A.   +9 more
europepmc   +1 more source

Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial. [PDF]

ESMO Open
Zhou YW, Wei GX, Chen XR, Cao P, Wei MT, Fang C, Deng XB, Li L, Wang C, Shu Y, Wang ZQ, Yu YY, Meng WJ, Qiu M.   +13 more
europepmc   +1 more source